Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Clinical Therapeutics

• Publication date

  2008-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.clinthera.2008.03.005PMID 18405789
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes.

  2008cited by this paper
• Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes.

  2007cited by this paper
• Effects of Dipeptidyl Peptidase-4 Inhibition on Gastrointestinal Function, Meal Appearance, and Glucose Metabolism in Type 2 Diabetes

  2007cited by this paper
• The role of gut hormones in glucose homeostasis.

  2007cited by this paper
• Vildagliptin in Drug-naïve Patients with Type 2 Diabetes: A 24-Week, Double-blind, Randomized, Placebo-controlled, Multiple-dose Study

  2007cited by this paper
• The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion.

  2007cited by this paper
• Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double‐blind, non‐inferiority trial

  2007cited by this paper
• Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes*

  2007cited by this paper
• Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV.

  2007cited by this paper
• Efficacy and tolerability of the dipeptidyl peptidase‐4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes

  2006cited by this paper
• The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.

  2006cited by this paper
• Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.

  2006cited by this paper
• Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes.

  2005cited by this paper
• Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9.

  2005cited by this paper
• Improved glycaemic control with dipeptidyl peptidase‐4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response

  2005cited by this paper
• Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double‐blind, placebo‐controlled studies with single oral doses

  2005cited by this paper
• Circulation and Degradation of GIP and GLP-1

  2004cited by this paper
• Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes

  2003cited by this paper
• Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients.

  2001cited by this paper
• Design and Analysis of Bioavailability and Bioequivalence Studies

  1999cited by this paper
• Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.

  1993cited by this paper
• Clinical pharmacokinetics : concepts and applications

  1989cited by this paper
• Analysis of Extreme Values

  1950cited by this paper

• A physiologically-based quantitative systems pharmacology model for mechanistic understanding of the response to alogliptin and its application in patients with renal impairment

  2025influential citation
• Different analytical methods for quantitative determination of alogliptin benzoate as single drug either in a biological sample or pharmaceutical dosage forms

  2024cites this paper
• Effect of Teneligliptin 20 mg Twice Daily on Glucagon-Like Peptide-1 Levels and Its Influence on Non-Glycemic Components in Non-Diabetic Obese Individuals

  2024cites this paper
• Development of Long-Acting Dipeptidyl Peptidase-4 Inhibitors: Structural Evolution and Long-Acting Determinants.

  2023cites this paper
• Effect of teneligliptin 20 mg twice daily on glucagon like-peptide-1 (GLP-1) levels and its in�uence on non-glycemic components in non-diabetic obese individuals

  2023cites this paper
• Pharmacotherapy of type 2 diabetes: An update and future directions.

  2022cites this paper
• In Silico Development of Combinatorial Therapeutic Approaches Targeting Key Signaling Pathways in Metabolic Syndrome

  2022cites this paper
• Role of Dipeptidyl Peptidase 4 Inhibitors in Antidiabetic Treatment

  2022cites this paper
• Exposure–Response Analysis of Cardiovascular Outcome Trials With Incretin-Based Therapies

  2022cites this paper
• Construction and application of highly sensitive spinel nanocrystalline zinc chromite decorated multiwalled carbon nanotube modified carbon paste electrode (ZnCr2O4@MWCNTs/CPE) for electrochemical determination of alogliptin benzoate in bulk and its dosage form: green chemistry assessment

  2022cites this paper
• Comparison of Metformin and Alogliptin Fixed-Dose Tablets Once a Morning Versus Once an Evening Using Continuous Glucose Monitoring (AMPM Study): An Open-Label Randomized Cross-Over Trial

  2021cites this paper
• Combinatorial approaches using an AI/ML-driven drug development platform targeting insulin resistance, lipid dysregulation, and inflammation for the amelioration of metabolic syndrome in patients

  2021cites this paper
• An overview of alogliptin + pioglitazone for the treatment of type 2 diabetes

  2021cites this paper
• DEVELOPMENT OF SUSTAINED RELEASE ALOGLIPTIN TABLETS USING A MULTIPARTICULATES SYSTEM MADE OF BENTONITE

  2021cites this paper
• First-in-Human, Single-Ascending Dose and Food Effect Studies to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Cetagliptin, a Dipeptidyl Peptidase-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus

  2021cites this paper
• Intestinal Absorption of Alogliptin Is Mediated by a Fruit-Juice-Sensitive Transporter.

  2021cites this paper
• Unveiling the interaction mechanism of alogliptin benzoate with human serum albumin: Insights from spectroscopy, microcalorimetry, and molecular docking and molecular dynamics analyses.

  2020cites this paper
• Salting-out induced liquid–liquid microextraction for alogliptin benzoate determination in human plasma by HPLC/UV

  2020cites this paper
• Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus

  2020cites this paper
• The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Directly Enhances the Contractile Recovery of Mouse Hearts at a Concentration Equivalent to that Achieved with Standard Dosing in Humans

  2020cites this paper
• Immunohistochemical Pharmacokinetics of the Anti-diabetes Drug Alogliptin in Rat Kidney and Liver

  2020cites this paper
• Determination of pioglitazone, its metabolite and alogliptin in human plasma by a novel LC-MS/MS method; application to a pharmacokinetic study.

  2019cites this paper
• Single-dose escalation study of yogliptin in healthy Chinese volunteers.

  2019cites this paper
• Analysis and bio-analysis of omarigliptin, trelagliptin and alogliptin: Applied to biological samples and degradation kinetic study

  2019cites this paper
• Enantioselective Box Behenken Optimized HPLC-DAD Method for the Simultaneous Estimation of Alogliptin Enantiomorphs in Pharmaceutical Formulations and their Pharmacokinetic Study in Rat Plasma

  2019cites this paper
• Immunohistochemistry for Anti-diabetes Drug, Alogliptin Using a Newly Prepared Monoclonal Antibody: Its Precise Localization in Rat Small Intestine

  2019cites this paper
• An up-to-date evaluation of alogliptin benzoate for the treatment of type 2 diabetes

  2019cites this paper
• Alogliptin abates memory injuries of hepatic encephalopathy induced by acute paracetamol intoxication via switching‐off autophagy‐related apoptosis

  2018cites this paper
• EVALUATION OF ANTIDIABETIC DRUG ALOGLIPTIN FOR THE TREATMENT OF INFLAMMATION IN RATS

  2018cites this paper
• Modular Access to N-Substituted cis 5-Amino-3-hydroxypiperidines.

  2017cites this paper
• Enhanced LC-MS/MS analysis of alogliptin and pioglitazone in human plasma: Applied to a preliminary pharmacokinetic study.

  2017cites this paper
• Evaluation of drug efficacy of DPP‐4 inhibitors based on theoretical analysis with pharmacokinetics and pharmacodynamics

  2017cites this paper
• Characterization of the post-prandial insulinemic response and low glycaemic index of a soy beverage

  2017cites this paper
• Enhanced LC-MS/MS determination of alogliptin and metformin in plasma: Application to a pharmacokinetic study

  2017cites this paper
• DPP-4 Inhibitors

  2017cites this paper
• Renal safety of newer medications

  2016cites this paper
• Application of pharmacometric approaches to evaluate effect of weight and renal function on pharmacokinetics of alogliptin.

  2016cites this paper
• Quantitative prediction of human pharmacokinetics and pharmacodynamics of imigliptin, a novel DPP-4 inhibitor, using allometric scaling, IVIVE and PK/PD modeling methods.

  2016cites this paper
• ANALYTICAL METHOD DEVELOPMENT AND VALIDATION OF ALOGLIPTIN BY RP-HPLC METHOD

  2016cites this paper
• Treatment of type 2 diabetes: the stability of the effectiveness of hypoglycemic medications

  2016cites this paper
• Dipeptidyl Peptidase-4 Inhibitor Increases Vascular Leakage in Retina through VE-cadherin Phosphorylation

  2016cites this paper
• Alogliptin for the treatment of type 2 diabetes: a drug safety evaluation

  2016influential citation
• Isolation and characterization of related substances in alogliptin benzoate by LC-QTOF mass spectrometric techniques.

  2016cites this paper
• Alogliptin + metformin combination for the treatment of type 2 diabetes mellitus

  2016cites this paper
• Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus

  2015influential citation
• An update on the clinical pharmacology of the dipeptidyl peptidase 4 inhibitor alogliptin used for the treatment of type 2 diabetes mellitus

  2015cites this paper
• Diabetes therapies in hemodialysis patients: Dipeptidase-4 inhibitors.

  2015cites this paper
• Alogliptin, a dipeptidyl peptidase-4 inhibitor, regulates the atrial arrhythmogenic substrate in rabbits.

  2015cites this paper
• Pharmacokinetics and clinical evaluation of the alogliptin plus pioglitazone combination for type 2 diabetes

  2015cites this paper
• Role of dipeptidyl peptidase-4 inhibitors in new-onset diabetes after transplantation

  2015cites this paper
• Retrospective and Prospective Human Intravenous and Oral Pharmacokinetic Projection of Dipeptidyl peptidase-IV Inhibitors Using Simple Allometric Principles - Case Studies of ABT-279, ABT-341, Alogliptin, Carmegliptin, Sitagliptin and Vildagliptin.

  2015cites this paper
• Alogliptin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus

  2015cites this paper
• Multiple system atrophy : a translational approach Characterization of the insulin/IGF-1 signaling pathway

  2015cites this paper
• Discovery of Linagliptin for the Treatment of Type 2 Diabetes Mellitus

  2015cites this paper
• Comparación de la eficacia de los

  2015cites this paper
• Alogliptin benzoate for management of type 2 diabetes

  2015cites this paper
• Alogliptin in combination with metformin and pioglitazone for the treatment of type 2 diabetes mellitus

  2014cites this paper
• Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: targets for disease modification?

  2014influential citation
• DPP-4 inhibitors: pharmacological differences and their clinical implications

  2014cites this paper
• Alogliptin for treatment of type 2 diabetes

  2014cites this paper
• Alogliptin: A new dipeptidyl peptidase-4 inhibitor for the management of type 2 diabetes mellitus.

  2014cites this paper
• Erratum to: Pharmacokinetics, safety, and efficacy of DPP-4 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus and renal or hepatic impairment. A systematic review of the literature

  2014cites this paper
• Linagliptin: from bench to bedside

  2014cites this paper
• Alogliptin in combination with metformin and pioglitazone for the treatment of type 2 diabetes mellitus

  2014cites this paper
• Alogliptin benzoate for the treatment of type 2 diabetes

  2014influential citation
• Regulation of glucose homeostasis by GLP-1.

  2014cites this paper
• The pharmacokinetic considerations and adverse effects of DDP-4 inhibitors

  2014cites this paper
• Glucose-lowering drugs in patients with chronic kidney disease: a narrative review on pharmacokinetic properties.

  2014cites this paper
• Pharmacokinetics, safety, and efficacy of DPP-4 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus and renal or hepatic impairment. A systematic review of the literature

  2014cites this paper
• Alogliptin for the treatment of Type 2 diabetes

  2014cites this paper
• Dipeptidyl peptidase‐4 inhibitors: pharmacokinetics, efficacy, tolerability and safety in renal impairment

  2014cites this paper
• Diabetes treatment in patients with renal disease: Is the landscape clear enough?

  2014cites this paper
• US FDA APPROVED NEW DRUG ALOGLIPTIN: A DPP-4 INHIBITOR FOR TREATMENT OF PATIENTS WITH TYPE 2 DIABETES

  2013cites this paper
• Efficacy of alogliptin in type 2 diabetes treatment: a meta-analysis of randomized double-blind controlled studies

  2013cites this paper
• Ionic Liquid as an Efficient and Recyclable Reaction Medium for the Synthesis of Pyrido[2,3‐d]pyrimidines

  2013cites this paper
• ANALYTICAL METHOD DEVELOPMENT AND VALIDATION OF ALOGLIPTIN AND METFORMIN HYDROCHLORIDE TABLET DOSAGE FORM BY RP-HPLC METHOD

  2013cites this paper
• The dipeptidyl peptidase-4 inhibitor alogliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis

  2013cites this paper
• Alogliptin

  2013influential citation
• Population pharmacokinetic/pharmacodynamic analysis of the DPP-4 inhibitor linagliptin in Japanese patients with type 2 diabetes mellitus.

  2013cites this paper
• Efficacy and safety of alogliptin in type 2 diabetic patients undergoing hemodialysis

  2013cites this paper
• Alogliptin: New Addition to Existing Gliptins for the Management of Type-2 Diabetes Mellitus

  2013cites this paper
• Method for determining enantiomer impurity in alogliptin crude drug and preparation by virtue of HPLC

  2013cites this paper
• New strategy for the treatment of type 2 diabetes mellitus with incretin-based therapy

  2013cites this paper
• Alogliptin

  2013cites this paper
• Clinical Pharmacokinetics and Pharmacodynamics of Linagliptin

  2012cites this paper
• Quantitative Model of the Relationship Between Dipeptidyl Peptidase‐4 (DPP‐4) Inhibition and Response: Meta‐Analysis of Alogliptin, Saxagliptin, Sitagliptin, and Vildagliptin Efficacy Results

  2012cites this paper
• Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors.

  2012cites this paper
• Alogliptin benzoate for the treatment of type 2 diabetes

  2012influential citation
• Renal and Cardiac Effects of DPP4 Inhibitors – from Preclinical Development to Clinical Research

  2012cites this paper
• Incretin Therapies in the Management of Patients with Type 2 Diabetes Mellitus and Renal Impairment

  2012cites this paper
• Comparative Clinical Pharmacokinetics of Dipeptidyl Peptidase-4 Inhibitors

  2012cites this paper
• Novel serine protease dipeptidyl peptidase IV inhibitor: alogliptin.

  2012cites this paper
• Clinical pharmacology of incretin therapies for type 2 diabetes mellitus: implications for treatment.

  2011cites this paper
• Small molecule dipeptidylpeptidase IV inhibitors under investigation for diabetes mellitus therapy

  2011cites this paper
• Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways.

  2011cites this paper
• Alogliptin: A DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus

  2011cites this paper
• Linagliptin: a novel dipeptidyl peptidase 4 inhibitor with a unique place in therapy

  2011cites this paper
• Long-Term Dipeptidyl-Peptidase 4 Inhibition Reduces Atherosclerosis and Inflammation via Effects on Monocyte Recruitment and Chemotaxis

  2011cites this paper
• Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice.

  2011cites this paper
• Pharmacology of Dipeptidyl Peptidase-4 Inhibitors

  2011cites this paper